EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Bidirectional EF1 Promoter System for Armoring CD19 CAR-T Cells with Secreted Anti-PD1 Antibodies

Asmita Khaniya iD, Nattarika Khuisangeam, Supannikar Tawinwung iD, Koramit Suppipat, Nattiya Hirankarn

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262311566 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Asmita Khaniya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence in Immunology and Immune-Mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 1…. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Promoter Regions, Genetic, Antigens, CD19, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Research Council of Thailand (NRCT): High-Potential Research Team Grant Program, Ratchadapisek Somphot Matching Fund, Faculty of Medicine, Chulalongkorn University, National Research Council of Thailand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies is often limited by T cell exhaustion, which is frequently driven by the PD-1/PD-L1 immune checkpoint axis. To overcome this, we developed an “armored” CAR-T cell strategy using a novel bidirectional promoter system. We engineered a single vector to co-express a CD19-specific CAR alongside a secreted anti-PD1 molecule, in either a full-length antibody or a single-chain variable fragment (scFv) format, using the Sleeping Beauty (SB) transposon system. The sequences for the anti-PD1 modules were derived from the clinical antibody nivolumab. Both armored constructs demonstrated robust CAR expression, comparable to or higher than conventional CAR-T cells, and proliferated significantly more than untransfected controls. The engineered cells successfully secreted their anti-PD1 payloads, with the full-length antibody showing more sustained secretion than the scFv. This autocrine blockade resulted in significantly reduced surface PD1 expression on the armored CAR-T cells. Functionally, the anti-PD1-secreting cells exhibited superior cytotoxicity against PD-L1-positive Raji target cells, particularly at low effector-to-target ratios. Critically, in a serial rechallenge assay designed to simulate chronic antigen exposure, both armored CAR-T cell groups showed markedly enhanced proliferation and persistence compared to conventional CAR-T cells, which failed to expand after repeated stimulation. Our findings validate the bidirectional EF1 promoter as an efficient system for generating multi-functional T cells and demonstrate that armoring CAR-T cells with secreted anti-PD1 antibodies is a potent strategy to enhance their persistence and anti-tumor efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorPromoter Regions, GeneticAntigens, CD19Immunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesHumansSingle-Chain AntibodiesCell Line, TumorB7-H1 AntigenNivolumab

Stichwörter der Autor:innen

CAR-T cellsanti-PD1bidirectional promoter

Substanzen

Programmed Cell Death 1 ReceptorAntigens, CD19Receptors, Chimeric AntigenSingle-Chain AntibodiesPDCD1 protein, humanCD19 molecule, humanB7-H1 AntigenNivolumab

Autor:innen und Institutionen

  • Center of Excellence in Immunology and Immune-Mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
  • Center of Excellence in Cellular Immunotherapy, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
  • Medical Microbiology Interdisciplinary Program, Graduate School, Chulalongkorn University, Bangkok 10330, Thailand.
  • Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
  • Department of Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

ORCID-Profile: Asmita Khaniya, Supannikar Tawinwung

Förderung

  • The National Research Council of Thailand (NRCT): High-Potential Research Team Grant Program
  • Ratchadapisek Somphot Matching Fund, Faculty of Medicine, Chulalongkorn University
  • National Research Council of Thailand
  • Ratchadapisek Somphot Fund for Postdoctoral Fellowship, Chulalongkorn University

Zitieren

APA

Khaniya, A., Khuisangeam, N., Tawinwung, S., Suppipat, K., & Hirankarn, N. (2025). A Bidirectional EF1 Promoter System for Armoring CD19 CAR-T Cells with Secreted Anti-PD1 Antibodies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311566

Vancouver

Khaniya A, Khuisangeam N, Tawinwung S, Suppipat K, Hirankarn N. A Bidirectional EF1 Promoter System for Armoring CD19 CAR-T Cells with Secreted Anti-PD1 Antibodies. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311566

BibTeX
@article{Khaniya2025,
  author = {Khaniya, Asmita and Khuisangeam, Nattarika and Tawinwung, Supannikar and Suppipat, Koramit and Hirankarn, Nattiya},
  title = {A Bidirectional EF1 Promoter System for Armoring CD19 CAR-T Cells with Secreted Anti-PD1 Antibodies},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262311566}
}
Kostenlos starten →